Abstract B76: Involuntary weight loss is an independent prognostic factor for overall survival and predicts better response to chemotherapy in high-grade serous ovarian cancer patients.

High-grade serous ovarian cancer (HGSOC) is the most common and very aggressive histological type of this neoplasm. Most of the patients require platinum-based chemotherapy following primary surgical treatment. Aim: to assess the prognostic value of involuntary weight loss between surgery and first cycle of chemotherapy. Material and methods: Out of 73 patients surgically treated for HGSOC, 64 received adjuvant chemotherapy. Prognostic value of several clinico-pathological features was assessed, including change of body weight between the day of primary debulking surgery and 1st cycle of chemotherapy. Survival analyses included the Kaplan–Meier method, log-rank test and Cox proportional hazards model. Results: The median follow-up was 47.25 months (range 17–79 months). Median change of body weight in the group of 64 patients who received chemotherapy was -3.5 kg (range from -33kg to +5kg). Higher weight loss values (median -5 kg, range: -1 to -33 kg) were observed in platinum-resistant patients (n=21) compared to platinum-sensitive ones (n=43) (median -3.5 kg, range: -5 to -14 kg) (p= 0.03). Weight loss between primary surgery and first cycle of chemotherapy was found to be independent prognostic factor for decreased OS (HR=3.8, CI 95%= 1.15-12.53, p=0.0285) and PFS (HR= 3.07; CI 95%= 1.28-7.38; p= 0.0123). Conclusions: Prevention of weight loss and nutritional wasting in HGSOC patients planned for adjuvant chemotherapy might improve results of treatment. Further prospective trials on nutrition of this group of patients are needed. Citation Format: J. Jan Sznurkowski, Maciej Pawlowski, Pawel Kabata. Involuntary weight loss is an independent prognostic factor for overall survival and predicts better response to chemotherapy in high-grade serous ovarian cancer patients. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: Exploiting Vulnerabilities; Oct 17-20, 2015; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(2 Suppl):Abstract nr B76.